Orthofix Medical Q3 revenue misses; cuts full-year guidance on weaker US Spine performance
OFIX•Orthofix Medical’s Q3 revenue rose 1% year over year to $207.9 million, below the $210.52 million consensus estimate, while adjusted EBITDA of $26 million also missed expectations. The company lowered its 2026 net sales outlook to $825 million-$830 million and adjusted EBITDA outlook to $86 million-$88 million.
1. Q3 results
Orthofix Medical reported Q3 revenue of $207.9 million, up 1% year over year and below the $210.52 million consensus estimate. Adjusted EBITDA was $26 million, versus a $27.05 million consensus estimate; the company cited lower Spine revenue and cost actions.
2. Lower 2026 outlook
The company lowered its 2026 net sales guidance to $825 million-$830 million from $845 million-$855 million and its non-GAAP adjusted EBITDA guidance to $86 million-$88 million from $95 million-$98 million. It anticipates a near-term impact from actions to improve US Spine execution and asset productivity.
3. Business lines
Limb Reconstruction net sales rose 8% year over year and Therapeutic Solutions net sales rose 4%. Orthofix cited weaker US Spine performance and commercial execution challenges as factors weighing on results.
